The phosphatidylinositol 3-kinase (PI3K) pathway is involved in many cellular functions including cell growth, metabolism, and transformation. Hyperactivation of this pathway contributes to tumorigenesis, therefore, PI3K is a major target for anticancer drug discovery. Since the PI3Kα isoform is implicated mostly in cancer, we conducted a high-throughput screening (HTS) campaign using a 3-step PI3K homogenous time-resolved fluorescence assay against this isoform bearing the H1047R mutation. A total of 288,000 synthetic and natural product-derived compounds were screened and of which, we identified 124 initial hits that were further selected by considering the predicted binding mode, relationship to known pan-assay interference compounds and previous descriptions as a lipid kinase inhibitor. A total of 24 compounds were then tested for concentration-dependent responses. These hit compounds provide novel scaffolds that can potentially be optimized to create novel PI3K inhibitors.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K) family of lipid kinases catalyzes the phosphorylation of 3-OH groups on the inositol ring of phosphatidylinositols embedded within membrane phospholipids [1] . PI3Ks can be divided into three different classes based on structural similarity, mechanism of activation, and substrate specificities [2, 3] . Class I PI3Ks catalyze the conversion of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) [4] . PIP 3 then acts as a secondary messenger to recruit and activate downstream signaling proteins to control important cellular processes including growth, metabolism, and migration [5, 6] .
Among the class I PI3Ks, the PI3Kα isoform, a heterodimer consisting of a p110α catalytic subunit encoded by PIK3CA and a p85α regulatory subunit encoded by PIK3R1, is implicated mostly in cancer [7] [8] [9] . The p110α catalytic subunit consists of five domains: an N-terminal adapter-binding domain that interacts with the regulatory subunit, a Ras-binding domain that mediates the interaction of p110 and Ras, a C2 domain that is involved in lipid binding, a helical domain that acts as a scaffold for other domains, and a C-terminal kinase domain where the ATP-binding and PIP 2 -binding sites are located [10] . PI3Kα is activated upon binding of receptor tyrosine kinases at phosphorylated tyrosines in YXXM motifs by SH2 domains in the p85α regulatory protein, relieving the inhibition of the p85α nSH2 domain on the p110α catalytic subunit [8] . PI3Kα is recruited to the lipid membrane upon activation, where it phosphorylates PIP 2 to PIP 3 , causing an intracellular signaling cascade [11] .
The PIK3CA gene is frequently mutated in many cancers, with the majority of mutations clustering in two hotspots [12] . One is located in the helical domain and involves the amino acid substitutions E542K and E545K (Catalog of somatic mutations in cancer, http://cancer.sanger.ac.uk). These mutations activate PI3Kα by mimicking and enhancing the growth factor-activated state and by relieving the inhibition imposed by the p85α nSH2 domain on the p110α subunit [13, 14] . The second hotspot is located in the kinase domain and involves substitutions of H1047 with R, L, or Y. These substitutions activate the enzyme by enhancing its membrane binding capability and increasing its access to PIP 2 [13, 15, 16] . These two hotspot activate the enzyme by different mechanisms and are synergistic in vitro [14, 17, 18] . However, the presence of both hotspot mutations has not yet been identified in the same tumor [9] . Both the E545K and the H1047R mutations are found in a range of cancer cell lines, such as breast, ovarian, prostate, and colon cancer [12, [19] [20] [21] .
Available crystal structures of PI3K from the Protein Data Bank (PDB) show that all known inhibitors interact with the ATP-binding site, which is located in a cleft between the N-terminal and C-terminal lobes of the kinase domain [9] . There are two regions in the cleft that are present in all isoforms: a hinge region located at the base of the ATP-binding cavity that provides a hydrogen bond donor and acceptor site through the backbone amide of a valine amino acid and a hydrophobic pocket termed the affinity pocket [22] . PI3Kα-selective inhibition can be achieved by interacting with the p110α-specific amino acid Gln859 in a non-conserved area called region I [21, [23] [24] [25] .
To date, a number of selective PI3Kα inhibitors have been developed, including the clinical candidate alpelisib and its analogs [23, [26] [27] [28] ; the PIK-75 series [29, 30] ; the NVS-PI3-2 series, which was discovered via high-throughput screening (HTS) [31] ; the GDC-0326 series [32] ; and the CNX-1351 series [33] . However, none of these inhibitors are selective for the H1047R oncogenic mutant over wild-type PI3Kα. As overexpression and mutation of PI3Kα are associated with cancer, developing inhibitors that are selective for PI3Kα may be more beneficial than inhibiting all class I PI3Ks [34] . Furthermore, selectively targeting the oncogenic mutant may widen the therapeutic window and reduce adverse side effects commonly associated with PI3K inhibition including hyperglycemia [35, 36] .
HTS is a method frequently used to discover hit compounds for drug development. Meanwhile, molecular docking has also become an essential tool often employed in drug discovery during the past few decades [37, 38] . Molecular docking is a computer-based method that can predict the conformation of small organic molecules in a target site on a protein of interest with a substantial degree of accuracy [39] . It can also be used as a screen to identify compounds within large libraries that best match the target site [37] . By using a combination of HTS and molecular docking, we aim to discover novel scaffolds for the development of PI3K inhibitors, and importantly, compounds that are potentially selective for H1047R mutant over wild-type PI3Kα.
MATERIAL AND METHODS
Protein expression and purification PI3K proteins were expressed and purified as previously reported [24] . Briefly, recombinant baculovirus-containing coding sequences for the full-length wild-type or H1047R p110α catalytic subunit and p85α regulatory subunit were used to infect Sf9 cells (Life Technologies, Carlsbad, CA, USA). Cultured cells were then centrifuged at 666 × g, and the pellets were resuspended in 20 mM Tris, 137 mM NaCl, pH 8.0, flash frozen in liquid nitrogen and stored frozen at −20°C. The frozen cell pellets were resuspended with gentle agitation in 25 mM Tris pH 8.0, 0.5% NP-40 alternative (Calbiochem, San Diego, CA, USA) and complete EDTA-free protease inhibitors (Roche, Basel, Switzerland) at room temperature until lysed as assessed by light microscopy. Cell lysates were centrifuged at 20,000 × g for 30 min at 4°C, the supernatant was removed and adjusted to 5% (v/v) glycerol, 150 mM NaCl, 7.5 mM imidazole, and 20 µg/mL RNAseA (Roche) and then passed through a 0.45 µm filter before loading onto a Talon-Co 2+ resin column (Clontech, Mountain View, CA, USA) pre-equilibrated in 25 mM Tris pH 8.0, 100 mM NaCl, 5% (v/v) glycerol, and 7.5 mM imidazole. The resin was washed with ten column volumes of 25 mM Tris pH 8.0, 150 mM NaCl, 7.5 mM imidazole, and 5% glycerol. Protein was eluted from the column with 25 mM Tris pH 8.0, 150 mM NaCl, 150 mM imidazole, and 5% glycerol. Eluted protein was dialyzed overnight in 50 mM Tris pH 8.0, 100 mM NaCl, 1 mM DTT, and 5% glycerol at 4°C. The dialyzed protein was centrifuged at 10,000 × g for 10 min at 4°C to remove precipitated material, and the supernatant was desalted to 40 mM NaCl using a Pharmacia Hi-trap desalting column (GE Healthcare; Little Chalfont, UK) according to the manufacturer's instructions. The desalted protein was applied to a MonoQ column (GE Healthcare) pre-equilibrated in 50 mM Tris pH 8.0, 40 mM NaCl, 1 mM DTT, 5% glycerol and fractionated over a gradient from 40-200 mM NaCl in the same buffer.
Compound library The compound library used in this study consisted of 288,000 synthetic and natural product-derived compounds solubilized in 100% DMSO prior to application in the HTS campaign. The structural diversity covered lactams, heterocycles, amides, secondary amides, sulfonates, sulfonamides, etc. One of the criteria for compound entry to this library is high purity (>95%). The collection is under strict quality control management. Both the purity and structures of randomly selected compounds were checked regularly (120 per month). Among the 8061 samples checked as of 27 April 2018, 99.06% showed correct structures according to the database information. The overall purity among them is 89.28%, which is sufficient for us to conduct HTS campaigns. This criterion applies to the 24 hits reported in this paper.
HTS campaign HTS was carried out in black 384-well microtiter plates (PerkinElmer, Boston, MA, USA) using the 3-step PI3K homogenous time-resolved fluorescence (HTRF) assay (Millipore, Burlington, MA, USA) following the manufacturer's instructions. Wild-type and H1047R PI3Kα were titrated and used at a concentration equivalent to their EC 65 values, and compounds were screened at a final concentration of 10 μM unless otherwise stated. Briefly, 0.5 μL of compounds were preincubated with 14.5 μL of enzyme and PIP 2 substrate for 10 min, before addition of 5 μL of ATP to achieve a final ATP concentration of 10 μM, similar to the Km of ATP as previously reported [40] . The total reaction volume was 20 μL, and the reaction was allowed to proceed for 45 min at room temperature before the addition of stop solution and detection mixture provided in the kit (Millipore). The plates were then incubated for 3 h in the dark and read using an EnVision Multilabel Plate Reader (PerkinElmer; 320/620/665). The experiment was done in duplicates. Hits identified from the primary screen using PI3Kα H1047R were subsequently rescreened against H1047R and counter-screened against wild-type PI3Kα at 10 μM.
Lipid kinase IC 50 determination IC 50 values were determined using the HTRF assay described above. Selected hits were dissolved and serially diluted in 100% DMSO, with a final in-assay concentration of 2.5% DMSO. The results were obtained using an EnSpire Multimode Plate Reader (PerkinElmer; 320/620/665) and analyzed using GraphPad Prism 6 nonlinear regression (curve fit), log (inhibitor) vs. response variable slope (four parameters) with constraints added at 0 and 100.
Molecular modeling
Hits discovered from the HTS experiments were prepared for docking using SYBYLX2.1.1. The protonation state for pH 7.0 was generated using ProtoPlex, up to ten stereocenters were enumerated using StereoPlex, and the 3D models were generated using CONCORD with the CCR limit set at 0.4. Molecular docking was performed using GOLD v5.2.2 [41] . The human PI3Kα structure (PDB: 2RD0) was prepared for docking as described previously [42] . The docking site was defined as an 18 Å cavity centered on the CD1 atom of Ile800, and the docking was carried out with the ChemScore scoring function modified for use with kinases. All protein and ligand atom types were generated automatically within GOLD. Where possible, known ring conformations were used, otherwise the ligand flexibility terms were kept at default values. The diverse solutions option New inhibitor screening against a mutant PI3Kα J Wang et al.
was turned on and set to 2.0 Å, each ligand was docked five times using a search efficiency of 200%, and five poses were kept per ligand. All poses were then rescored using the ChemScore Kinase scoring function with the ligand minimization and receptor-depth scaling options turned on.
Statistical analysis
Results were analyzed using GraphPad Prism 6 and representatives of at least two independent experiments in duplicate or triplicate. Statistical significance was determined using multiple ttests. *P < 0.05, **P < 0.01, ***P < 0.001.
Z' value was evaluated by 192 enzyme control wells and 192 noenzyme control wells before the HTS:
MEC indicates the mean value of enzyme control wells. SDEC indicates the standard deviation of enzyme control wells. MNEC indicates the mean value of no-enzyme control wells. SDNEC indicates the standard deviation of no-enzyme control wells.
Inhibition (%) was calculated using the following equation:
Signal test indicates the value of each compound-test well. Signal NEC indicates the mean value of no-enzyme control wells. Signal EC indicates the mean value of enzyme control wells.
RESULTS AND DISCUSSION

High-throughput screening campaigns against PI3Kα
To identify new scaffolds and discover hit compounds that are active against the H1047R mutant, an HTS campaign was performed on the PI3Kα H1047R mutant. The HTS campaign included an initial screen of 288,000 compounds, followed by subsequent confirmation on H1047R, counter-screening of active hits against wild-type PI3Kα and IC 50 determination of selected hits in wild-type and H1047R PI3Kα. The 288,000 compounds were divided into three batches and screened against H1047R PI3Kα at 10 μM. The Z' value of the screening assay was 0.42 with a signal to background ratio (S/B ratio) of 3.11 and a coefficient of variation (CV) value of 11% (Fig. 1) . The HTS results are summarized in Fig. 2 . Batch 1 consisted of 80,000 compounds and gave 76 hits with greater than 50% inhibition. For batches 2 and 3, the enzyme was less active than those used for batch 1, hence requiring more protein. To compensate for this and to increase the number of hit compounds, the cut-off for inhibition was lowered to 30%. These two combined batches consisted of 208,000 compounds and retrieved 112 hits with inhibition greater than 30%. Therefore, a total of 188 hits were identified from the HTS campaign. In the secondary screen, the 188 initial hits were rescreened against H1047R and then counter-screened at 10 μM against wild-type PI3Kα (Supplementary Figures 1-3) . This approach yielded a total of 124 confirmed hits, and statistical analysis was carried out to determine whether they were selective for the H1047R mutant. The identified hits either had minimal selectivity for H1047R over wild-type after further testing in concentration response assays or were not further investigated due to unfavorable structures. Therefore, it seems that most of the confirmed hits were not selective for H1047R PI3Kα over wild-type PI3Kα, suggesting that it is difficult to achieve selectivity by probing the in vitro catalytic activity. This finding is in agreement with studies showing that the increase in activity of the H1047R mutant is not due to increased catalytic site activity but rather is due to increased membrane binding [15, 16, 43] .
Identification of novel PI3Kα inhibitors
Although the HTS campaign did not yield hits that were selective for the H1047R mutant, the screen did discover some interesting structures. A major drawback in developing novel scaffolds is the undruggable nature of hit compounds; hence, the 188 initial hits were filtered for promiscuous compounds and non-drug-like groups. The pan-assay interference compounds (PAINS) substructure filter developed by Baell et al. [44] was used to remove compounds known to interfere with the assay through nonspecific mechanisms. An interpretation of this output is that any activity observed for the compounds that failed the PAINS filter might be related to mechanisms other than inhibiting the enzyme like a well-behaved reversible inhibitor. Of the 188 initial hits, only 102 compounds passed the PAINS filter, as implemented in SYBYLX2.1.1. They were also put through a filter for undesirable substructures that in general would not be found in drug-like molecules, which is also implemented in SYBYLX2.1.1. Of the 188 initial hits, 75 compounds passed the substructure filter, and only 53 compounds passed this and the PAINS filter.
Predicting a potential mechanism of inhibitory activity Since the hits identified were active against both wild-type PI3Kα and the H1047R mutant enzyme, molecular docking was used to predict potential binding poses for the ligands in the PI3Kα active site. This approach was performed to find compounds that participate in interactions considered important for PI3Kα inhibitors and to also identify compounds that potentially have novel mechanisms of action. All known PI3K inhibitors form hydrogen-bond interactions with the backbone amide of Val851 at the linker, and PI3Kα-selective inhibitors achieve their selectivity by interacting with the p110α-specific amino acid Gln859 [21, 23] . The five poses kept for each ligand were examined for a predicted hydrogen-bond interaction with the backbone amide of Val851 and the side chain carboxamide of Gln859 using the default hydrogen bond descriptor settings implemented in Hermes. Molecular docking data showed that of the 188 initial hits, 157 compounds were predicted to form hydrogen-bond interactions with the Val851 linker, and only three of these were also predicted to form a hydrogen bond with both polar groups of the Gln859 side chain as reported for PI3Kα-selective inhibitors [21, [23] [24] [25] . These docking results suggest that few of the active molecules are likely to be PI3Kα-selective, although the active compounds were not tested on other class I PI3K isoforms.
IC 50 determination of active hits Based on the combination of biochemical data, predicted binding modes and chemical structure analysis, 24 compounds from the confirmed hits were prioritized for further investigation. IC 50 values were determined against both the wild-type and H1047R mutant enzymes. From these candidates, three compounds (WNN0429-D004, WNN1560-A006, and WNN4101-D008) have scaffolds similar to previously described PI3K inhibitors, and another two (WNN1237-B004 and WNN1489-B003) possess an embedded hydrogen bond donor-acceptor motif found in kinase inhibitors [45, 46] . This result demonstrates that the HTS protocol employed is capable of discovering lipid kinase inhibitors that block the ATP-binding site.
The results showed that most of the compounds have IC 50 values in the low micromolar range and that none of them were significantly more potent against the H1047R mutant enzyme than against the wild-type enzyme (Table 1) . However, several novel structures were identified, and these may potentially act as starting points for future optimization to create potent PI3K inhibitors.
In summary, we presented the application of the PI3K homogenous time-resolved fluorescence assay to an HTS setting. In combination with molecular modeling, this approach led to the identification of hits with novel scaffolds, and our findings offer novel structures and promising tools for PI3K drug discovery.
